MCV4
Phase 1Biologic
CanSino Biologics Inc.MCV4 is one of 22 biologic programs targeting Influenza. It is currently in Phase 1.
1
Indications
6
Total Trials
5
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
MCV4
CanSino Biologics Inc.Phase 1
Fluvirin
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clinical Trial3 trials
Influenza1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCV4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company